医学
糖尿病性心肌病
糖尿病
心力衰竭
血脂异常
内科学
心肌病
心脏病学
2型糖尿病
肥胖
重症监护医学
内分泌学
作者
Liliana E. Favaloro,Roxana Ratto,Carla Musso
标识
DOI:10.2174/1573402117666210406111927
摘要
: The relationship between diabetes and risk of heart failure has been described in previous trials, releasing the importance of the hyperglycemic state that, added to other risk factors, favors the development of coronary heart disease. The mechanism by which, in the absence of hypertension, obesity and/or dyslipidemia, diabetic patients develop cardiomyopathy has been less studied. : Recently, the Sodium Glucose Co-transporter type 2 inhibitors (SGLT2 inhibitors) used for the treatment of heart failure patients with or without diabetes has been a breakthrough in the field of medicine. : This review describes the established pathophysiology of diabetic cardiomyopathy and SGLT2 inhibitors, their mechanisms of action, and benefits in this group of patients.
科研通智能强力驱动
Strongly Powered by AbleSci AI